Navigation Links
New strategy for inhibiting virus replication
Date:8/14/2009

Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.

The team led by Professor Dr. Ralf Bartenschlager, Director of the Department of Molecular Virology at the Hygiene Institute of Heidelberg University Hospital, has identified a protein in infected liver cells that is essential for hepatitis C virus replication. Inhibiting this protein is highly efficient in blocking virus replication. The study is to be published in the prestigious journal Public Library of Science Pathogens.

Viruses need cellular proteins for replication

More than 170 million people worldwide are affected by chronic hepatitis C. In up to 80 percent of infections, the virus can not be eliminated but persists in the infected individual. These chronically infected persons have a high risk of developing serious liver inflammation, liver cirrhosis and even a liver cell tumor.

Viruses contain only a minimum of genetic material and therefore need a host cell for replication. An essential cell factor required for hepatitis C virus replication is cyclophilin, which promotes the proper folding of proteins and the formation of large protein assemblies. Cyclophilin can be inhibited very efficiently by a drug used primarily in the context of organ transplantation the immunosuppressant cyclosporin. In search for better tolerated drugs to trea chronic hepatitis C, derivatives of cyclosporin were developed that no longer suppress the immune system, but still effectively inhibit cyclophilin. One of these derivatives is DEBIO-025. Although the exact antiviral mechanism by which DEBIO-025 inhibits hepatitis C virus replication is not yet known, clinical studies are already being conducted.

The critical protein is cyclophilin A

A cell contains numerous variants of cyclophilins that are inhibited by cyclosporin and cyclosporin derivatives. The research team from Heidelberg analyzed liver cells to determine which cyclophilin is critical for hepatitis C virus replication. They found that only blocking cyclophilin A leads complete inhibition of virus replication and this cyclophilin is also the target of DEBIO-025.

Two complementary effects are responsible for the inhibition of hepatitis C virus replication: cyclophilin A is required both for the formation of the viral replication machinery and for the activity of a viral enzyme that is essential for the assembly of infectious virus particles. Inhibiting cyclophilin A with DEBIO-025 thus blocks hepatitis C virus replication from two different sides. By contrast, blocking cyclophilin B had no effect.

"The therapeutic potential of inhibiting cellular factors essential for virus replication has thus far hardly been tapped," explains Professor Bartenschlager. "But this approach has the major advantage that resistance arises less frequently and to a lesser extent in comparison to therapies directly targeting viral factors."


'/>"/>

Contact: Dr. Ralf Bartenschlager
Ralf_Bartenschlager@med.uni-heidelberg.de
062-215-64569
University Hospital Heidelberg
Source:Eurekalert

Related biology news :

1. A combined tooth-venom arsenal revealed as key to Komodo dragons hunting strategy
2. New therapeutic strategy could target toxic protein in most patients with Huntingtons disease
3. Therapeutic hypothermia is promising strategy to minimize tissue damage
4. RNA research strategy for Europe takes shape
5. Hope for a rabies eradication strategy in Africa
6. Mitochondria could be a target for therapeutic strategy for Alzheimers disease patients
7. GUMC researchers hone in on new strategy to treat common infection
8. Effects of anthropogenic sound on marine mammals -- a research strategy
9. Scientists uncover Ebola cell-invasion strategy
10. New study raises concerns about proposed mitigation strategy for marine bycatch
11. Novel therapeutic strategy for colon cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):
(Date:9/21/2017)... ... 21, 2017 , ... Biorez, Inc. , a regenerative ... Entrepreneur in Residence at Medtronic, Inc., to serve as an Independent Director on ... for anterior cruciate ligament (ACL) reconstruction that is designed to stabilize the knee ...
(Date:9/20/2017)... ... September 20, 2017 , ... Cybrexa Therapeutics ... Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar ... Cybrexa’s president and CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary ...
(Date:9/20/2017)... Station, TX (PRWEB) , ... ... ... Services, LLC (IPS), a leading global provider of engineering, architecture, project controls, ... provider of prefabricated cleanrooms, today announced the unveiling of the iCON™ brand ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... examining the effects of exoskeleton-assisted walking on gait parameters and neuromuscular activity ... "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking session" (doi:10.1080.10790268.2017.1314900) was ...
Breaking Biology Technology: